Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
77.4M
-
Number of holders
-
77
-
Total 13F shares, excl. options
-
26.5M
-
Shares change
-
+1.32M
-
Total reported value, excl. options
-
$252M
-
Value change
-
-$9.25M
-
Number of buys
-
49
-
Number of sells
-
-24
-
Price
-
$9.51
Significant Holders of Mineralys Therapeutics, Inc. - Common Stock (MLYS) as of Q3 2023
90 filings reported holding MLYS - Mineralys Therapeutics, Inc. - Common Stock as of Q3 2023.
Mineralys Therapeutics, Inc. - Common Stock (MLYS) has 77 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 26.5M shares
of 77.4M outstanding shares and own 34.26% of the company stock.
Largest 10 shareholders include Samsara BioCapital, LLC (4.52M shares), RA CAPITAL MANAGEMENT, L.P. (3.18M shares), ADAMS STREET PARTNERS LLC (2.3M shares), BRAIDWELL LP (2.02M shares), SR ONE CAPITAL MANAGEMENT, LP (1.79M shares), FMR LLC (1.19M shares), Rock Springs Capital Management LP (1.17M shares), Laurion Capital Management LP (970K shares), VANGUARD GROUP INC (938K shares), and RTW INVESTMENTS, LP (922K shares).
This table shows the top 77 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.